Bayer/J&J's Xarelto Gets Advisory Cmte. Endorsement In A-Fib, But Not First-Line Use
• By The Pink Sheet Daily
Cardiovascular and Renal Drugs Advisory Committee votes 9-2, with one abstention, in favor of approval, but more than half the panelists said the indication should be limited to patients who fail other anticoagulant therapy.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights